$39.23
7.43% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US69366J2006
Symbol
PTCT
Sector
Industry

PTC Therapeutics, Inc. Target price 2024 - Analyst rating & recommendation

PTC Therapeutics, Inc. Classifications & Recommendation:

Buy
44%
Hold
38%
Sell
19%

PTC Therapeutics, Inc. Price Target

Target Price $44.21
Price $39.23
Potential
Number of Estimates 14
14 Analysts have issued a price target PTC Therapeutics, Inc. 2025 . The average PTC Therapeutics, Inc. target price is $44.21. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 16 analysts: 7 Analysts recommend PTC Therapeutics, Inc. to buy, 6 to hold and 3 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the PTC Therapeutics, Inc. stock has an average upside potential 2025 of . Most analysts recommend the PTC Therapeutics, Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 937.82 777.18
34.20% 17.13%
EBITDA Margin -12.03% -11.96%
72.09% 0.57%
Net Margin -68.68% -49.71%
19.94% 27.62%

15 Analysts have issued a sales forecast PTC Therapeutics, Inc. 2024 . The average PTC Therapeutics, Inc. sales estimate is

$777m
Unlock
. This is
13.71% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$814m 9.62%
Unlock
, the lowest is
$725m 19.54%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $938m 34.20%
2024
$777m 17.13%
Unlock
2025
$706m 9.21%
Unlock
2026
$836m 18.53%
Unlock
2027
$975m 16.55%
Unlock
2028
$1.0b 3.87%
Unlock

6 Analysts have issued an PTC Therapeutics, Inc. EBITDA forecast 2024. The average PTC Therapeutics, Inc. EBITDA estimate is

$-92.9m
Unlock
. This is
525.23% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-45.6m 308.90%
Unlock
, the lowest is
$-146m 768.19%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-113m 62.55%
2024
$-92.9m 17.64%
Unlock
2025
$-82.0m 11.69%
Unlock
2026
$46.4m 156.55%
Unlock

EBITDA Margin

2023 -12.03% 72.09%
2024
-11.96% 0.57%
Unlock
2025
-11.63% 2.76%
Unlock
2026
5.55% 147.72%
Unlock

15 PTC Therapeutics, Inc. Analysts have issued a net profit forecast 2024. The average PTC Therapeutics, Inc. net profit estimate is

$-386m
Unlock
. This is
15.47% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-300m 34.34%
Unlock
, the lowest is
$-493m 7.91%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-644m 7.45%
2024
$-386m 40.01%
Unlock
2025
$-303m 21.66%
Unlock
2026
$-148m 51.07%
Unlock
2027
$-93.9m 36.60%
Unlock
2028
$-21.2m 77.43%
Unlock

Net Margin

2023 -68.68% 19.94%
2024
-49.71% 27.62%
Unlock
2025
-42.90% 13.70%
Unlock
2026
-17.71% 58.72%
Unlock
2027
-9.63% 45.62%
Unlock
2028
-2.09% 78.30%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -8.37 -5.02
7.45% 40.02%
P/E negative
EV/Sales 3.10

15 Analysts have issued a PTC Therapeutics, Inc. forecast for earnings per share. The average PTC Therapeutics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-5.02
Unlock
. This is
15.49% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-3.90 34.34%
Unlock
, the lowest is
$-6.41 7.91%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-8.37 7.45%
2024
$-5.02 40.02%
Unlock
2025
$-3.93 21.71%
Unlock
2026
$-1.92 51.15%
Unlock
2027
$-1.22 36.46%
Unlock
2028
$-0.28 77.05%
Unlock

P/E ratio

Current -6.61 208.88%
2024
-7.81 18.15%
Unlock
2025
-9.97 27.66%
Unlock
2026
-20.38 104.41%
Unlock
2027
-32.15 57.75%
Unlock
2028
-142.41 342.95%
Unlock

Based on analysts' sales estimates for 2024, the PTC Therapeutics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.68 18.06%
2024
3.10 15.82%
Unlock
2025
3.42 10.15%
Unlock
2026
2.88 15.63%
Unlock
2027
2.48 14.20%
Unlock
2028
2.38 3.73%
Unlock

P/S ratio

Current 3.36 91.64%
2024
3.89 15.89%
Unlock
2025
4.29 10.15%
Unlock
2026
3.62 15.63%
Unlock
2027
3.10 14.20%
Unlock
2028
2.99 3.73%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today